Hologic divests drug
This article was originally published in The Gray Sheet
Women's health device maker divests Gestiva, its "non-core" drug for the prevention of preterm birth, to KV Pharmaceutical for $82 million in a deal announced Jan. 22. The drug, which is pending FDA approval, was part of Hologic's October purchase of cervical cancer test firm Cytyc (1"The Gray Sheet" May 28, 2007, p. 10)
You may also be interested in...
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.